Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575

Modulation of tryptophan catabolism by regulatory T cells

Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020

Immune Tolerance Induction by Integrating Innate and Adaptive Immune Regulators

Suzuki, J., Ricordi, C., & Chen, Z. (2010) · Cell Transplantation · doi:10.3727/096368909x480314 · Cited by 25

Association of 3′ nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population

Partyka, A., Tupikowski, K., Kołodziej, A., Zdrojowy, R., Hałoń, A., Małkiewicz, B., Dembowski, J., Frydecka, I., & Karabon, L. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.04.010 · Cited by 25

Cblb -deficient T cells are less susceptible to PD-L1-mediated inhibition

Peer, S., Baier, G., & Gruber, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18360 · Cited by 26

Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody

Dao, T., Mun, S. S., Scott, A., Jarvis, C. A., Korontsvit, T., Yang, Z., Liu, L., Klatt, M. G., Guerreiro, M., Selvakumar, A., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1570778 · Cited by 25

Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes

Marei, H. E. S., Al-Thani, A., Caceci, T., Arriga, R., Sconocchia, T., Ottaviani, A., Lanzilli, G., Roselli, M., Caratelli, S., Cenciarelli, C., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.002 · Cited by 25

The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure

Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 28

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

Rajani, K. R., & Vile, R. G. (2015) · Viruses · doi:10.3390/v7112914 · Cited by 25

CTLA-4 antibodies: new directions, new combinations.

Funt, S. A., Page, D. B., Wolchok, J. D., & Postow, M. A. (2014) · PubMed · Cited by 24

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Carbonnel, F., Soularue, É., Coutzac, C., Chaput, N., Mateus, C., Lepage, P., & Robert, C. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0613-x · Cited by 26

The immunotherapeutic landscape in non–small cell lung cancer and its surgical horizons

Rhodin, K. E., Rucker, A. J., Ready, N., D’Amico, T. A., & Antonia, S. J. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.08.138 · Cited by 24

Colorectal Cancer and Purinergic Signalling: An Overview

Roliano, G. G., Azambuja, J. H., Brunetto, V., Butterfield, H. E., Kalil, A. N., & Braganhol, E. (2022) · Cancers · doi:10.3390/cancers14194887 · Cited by 26

Blockade of CTLA-4 Decreases the Generation of Multifunctional Memory CD4+ T Cells In Vivo

Rudolph, M., Hebel, K., Miyamura, Y., Maverakis, E. M., & Brunner-Weinzierl, M. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003381 · Cited by 24

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Ryan, J. M., Wasser, J. S., Adler, A. J., & Vella, A. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1152256 · Cited by 24

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002

Ring, E. K., Li, R., Moore, B. P., Nan, L., Kelly, V. M., Han, X., Beierle, E. A., Markert, J. M., Leavenworth, J. W., Gillespie, G. Y., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.09.003 · Cited by 24

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Rosell, R., González‐Cao, M., Karachaliou, N., Viteri, S., Espinosa, D. M., Teixidó, C., Ruiz, J. S., Molina‐Vila, M. Á., & Santarpía, M. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s55176 · Cited by 24

Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers

Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23

Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists

Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23

Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine

Albershardt, T. C., Parsons, A. J., Reeves, R. S., Flynn, P., Campbell, D. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.034 · Cited by 23

Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma

Isazadeh, A., Hajazimian, S., Garshasbi, H., Shadman, B., Baghbanzadeh, A., Chavoshi, R., Taefehshokr, S., Jadid, M. F. S., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29905 · Cited by 23

A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer

Hu, D., Cao, Q., Tong, M., Ji, C., Li, Z., Huang, W., Jin, Y., Tong, G., Wang, Y., Li, P., et al. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01172-5 · Cited by 23

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23

ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance

Podojil, J. R., Hecht, I., Chiang, M.-Y., Vaknin, I., Barbiro, I., Novik, A., Neria, E., Rotman, G., & Miller, S. D. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700326 · Cited by 22

Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma

Moskovitz, J., & Ferris, R. (2018) · Journal of dentistry research · doi:10.1177/0022034518759464 · Cited by 23

p110δ PI3K as a therapeutic target of solid tumours

Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 23

Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Minowa, T., Molgora, M., Williams, C. D., Chaib, M., Highsmith, A. M., Pineda, J. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114875 · Cited by 28

Vaccines against advanced melanoma

Blanchard, T., Srivastava, P. K., & Duan, F. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.005 · Cited by 22

Immune checkpoint inhibitors for hepatocellular carcinoma

Jensen, C. E., Loaiza‐Bonilla, A., & Bonilla-Reyes, P. A. (2016) · Hepatic Oncology · doi:10.2217/hep-2016-0004 · Cited by 22

Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy

Patel, K. J., Siraj, S., Smith, C., Nair, M. P., Vishwanatha, J. K., & Basha, R. M. (2019) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2019031417 · Cited by 22

Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy

Jacquelot, N., Ghaedi, M., Warner, K., Chung, D. C., Crome, S. Q., & Ohashi, P. S. (2021) · Cancers · doi:10.3390/cancers13235967 · Cited by 22

Immune checkpoint inhibition in lymphoid disease

Eyre, T. A., & Collins, G. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13397 · Cited by 22

Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity

Kashima, H., Momose, F., Umehara, H., Miyoshi, N., Ogo, N., Muraoka, D., Shiku, H., Harada, N., & Asai, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156643 · Cited by 22

Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity

Gu, Y., Fan, C., Lu, R., Shao, B., Sang, Y., Huang, Q., Li, X., Meng, W., Mo, X., & Wei, Y.-Q. (2016) · Scientific Reports · doi:10.1038/srep32351 · Cited by 22

Recent advances in cancer immunology and immunology-based anticancer therapies

Kumar, S., Saini, R. V., & Mahindroo, N. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.126 · Cited by 21

Anti–CTLA‐4 synergizes with dendritic cell–targeted vaccine to promote IL‐3–dependent CD4+ effector T cell infiltration into murine pancreatic tumors

Zaidi, N., Quezada, S. A., Kuroiwa, J. M. Y., Zhang, L., Jaffee, E. M., Steinman, R. M., & Wang, B. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14049 · Cited by 22

New avenues for melanoma immunotherapy: Natural Killer cells?

Cristiani, C. M., Garofalo, C., Passacatini, L. C., & Carbone, E. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12861 · Cited by 22

Highlights on immune checkpoint inhibitors in non–small cell lung cancer

Shen, M., & Ren, X. (2017) · Tumor Biology · doi:10.1177/1010428317695013 · Cited by 21

Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials

Huynh, J. C., Patel, K. G., Gong, J., Cho, M. T., Malla, M., Parikh, A. R., & Klempner, S. J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00893-6 · Cited by 21

Modulation of T cell function and survival by the tumor microenvironment

Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22

Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)

Mousa, A. M., Enk, A. H., Hassel, J. C., & Reschke, R. (2024) · Cells · doi:10.3390/cells13191615 · Cited by 24

Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy

Stinchcombe, T. E. (2014) · Medical Oncology · doi:10.1007/s12032-014-0960-1 · Cited by 20

Treg Cells As Potential Cellular Targets for Functionalized Nanoparticles in Cancer Therapy

Jonuleit, H., Bopp, T., & Becker, C. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0197 · Cited by 21

Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules

D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 21

Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response

Qi, H., Sun, Z., Gao, T., Yao, Y., Yu, W., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01958-4 · Cited by 21

Advancements in melanoma cancer metastasis models

Melo, L. M. N., Kumar, S., Riess, V., Szylo, K. J., Eisenburger, R. T., Schadendorf, D., Ubellacker, J. M., & Tasdogan, A. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13078 · Cited by 20

METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment

Wang, L., & Peng, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-37807-5 · Cited by 20

Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions

Sharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 22

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

Tong, H., Wei, H., Smith, A. O., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.802049 · Cited by 20

Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer

Martı́n, P., Blanco-Domínguez, R., & Sánchez‐Díaz, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00586-4 · Cited by 18

Targeting the spectrum of immune checkpoints in prostate cancer

Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 19

Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

Wang, S.-L., Chen, S., Zhong, Q., & Liu, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04214-8 · Cited by 20

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors

Abenavoli, L., Montori, M., Svegliati‐Baroni, G., Argenziano, M. E., Giorgi, F., Scarlata, G. G. M., Ponziani, F. R., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59081427 · Cited by 21

Antitumor effect of plant-produced anti-CTLA-4 monoclonal antibody in a murine model of colon cancer

Bulaon, C. J. I., Khorattanakulchai, N., Rattanapisit, K., Sun, H., Pisuttinusart, N., Strasser, R., Tanaka, S., Soon‐Shiong, P., & Phoolcharoen, W. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1149455 · Cited by 19

Nanotechnology-Based Platforms to Improve Immune Checkpoint Blockade Efficacy in Cancer Therapy

Lahori, D., & Varamini, P. (2020) · Future Oncology · doi:10.2217/fon-2020-0720 · Cited by 19

Revisiting Immune-Based Therapies for Aggressive Follicular Cell–Derived Thyroid Cancers

French, J. D. (2013) · Thyroid · doi:10.1089/thy.2012.0566 · Cited by 18

CD4+ T cell dysfunction in cancer

Venkatesh, H., & Fong, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241417 · Cited by 19

A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma

Hanna, K. S. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2033 · Cited by 18

Present and Future Role of Immune Targets in Acute Myeloid Leukemia

Damiani, D., & Tiribelli, M. (2022) · Cancers · doi:10.3390/cancers15010253 · Cited by 19

Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studies.

Wang, L., Jiang, Z., Qiu, H., Tang, W., Duan, T., & Wang, L. (2015) · Europe PMC (PubMed Central) · Cited by 18

Dendritic Cell Subsets as Vectors and Targets for Improved Cancer Therapy

Palucka, K., Ueno, H., Roberts, L. K., Fay, J. W., & Banchereau, J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_48 · Cited by 18

Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art

Olin, M. R., Pluhar, G. E., Andersen, B. M., Shaver, R. L., Waldron, N. N., & Moertel, C. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014011577 · Cited by 18

Enhancing the Efficacy of Adoptive Cellular Therapy By Targeting Tumor-InDuced Immunosuppression

Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Neeson, P. J., & Darcy, P. K. (2015) · Immunotherapy · doi:10.2217/imt.15.16 · Cited by 18

Immunotherapy for Lung Cancer

Reinmuth, N., & Reck, M. (2016) · Oncology Research and Treatment · doi:10.1159/000446726 · Cited by 20

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

Tunger, A., Kießler, M., Wehner, R., Temme, A., Meier, F. E., Bachmann, M. P., & Schmitz, M. (2018) · Biomedicines · doi:10.3390/biomedicines6010026 · Cited by 18

CNS cancer immunity cycle and strategies to target this for glioblastoma

Ameratunga, M., Coleman, N., Welsh, L. C., Saran, F. H., & Lopez, J. S. (2018) · Oncotarget · doi:10.18632/oncotarget.24896 · Cited by 18

Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes

Sun, N.-Y., Chen, Y., Lin, H.-W., Chiang, Y., Chang, C.-F., Tai, Y., Chen, C., Sun, W., Chien, C. L., & Cheng, W. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.039 · Cited by 18

Neuroimmunity in amyotrophic lateral sclerosis: focus on microglia

Moțățăianu, A., Bărcuţean, L., & Bălașa, R. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1708949 · Cited by 17

Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4–Targeted Immunotherapy

Emerson, D. A., Rolig, A. S., & Redmond, W. L. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0338 · Cited by 18

KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsPreprint

LeBleu, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M. C., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · medRxiv · doi:10.1101/2025.03.03.25322827 · Cited by 18

New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer

Lin, M., Sun, X. K., & Lv, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.04.007 · Cited by 19

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma

Schoenfeld, D. A., Djureinovic, D., Su, D. G., Zhang, L., Lu, B. Y., Kamga, L., Mann, J. E., Huck, J. D., Hurwitz, M. E., Braun, D. A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.184545 · Cited by 17

Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies

Kelly, M., McNeel, D. G., Fisch, P., & Malkovský, M. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.11.001 · Cited by 17

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Morante, M., Pandiella, A., Crespo, P., & Herrero, A. (2022) · Biomolecules · doi:10.3390/biom12111562 · Cited by 19

Translating Treg Therapy in Humanized Mice

Hahn, S. A., Bellinghausen, I., Trinschek, B., & Becker, C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00623 · Cited by 18

Negative Correlation between Circulating CD4+FOXP3+CD127− Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria–Tetanus–Pertussis Vaccine Implies a Regulatory Role

Ndure, J., Noho‐Konteh, F., Adetifa, J. U., Cox, M., Barker, F., Le, M. T., Sanyang, L. C., Drammeh, A., Whittle, H. C., Clarke, E., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00921 · Cited by 17

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy

Kong, B. Y., Bolton, H. A., Kim, J. W., Silveira, P. A., Fromm, P. D., & Clark, G. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00050 · Cited by 19

Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies

Damei, I., Caidi, A., Auclin, É., Adam, J., Mella, S., Hasan, M., Tartour, É., Robert, C., Corgnac, S., & Mami‐Chouaib, F. (2025) · Nature Communications · doi:10.1038/s41467-025-60657-w · Cited by 21

Metabolism of Immune Cells in the Tumor Microenvironment

Jung, J. G., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_13 · Cited by 16

Checkpoint Inhibitors in Acute Myeloid Leukemia

Damiani, D., & Tiribelli, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061724 · Cited by 16

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma

Pennacchioli, E., Tosti, G., & Cocorocchio, E. (2013) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s24246 · Cited by 17

Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

Suárez, N., Alfaro, C., Dubrot, J., Palazón, A., Bolaños, E., Erro, L., Hervás‐Stubbs, S., Martínez‐Forero, I., Morales‐Kastresana, A., Martín‐Algarra, S., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25681 · Cited by 16

Liver Tumor Microenvironment

Tsilimigras, D. I., Ntanasis‐Stathopoulos, I., Moris, D., & Pawlik, T. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_14 · Cited by 16

PD-1 blockade: promoting endogenous anti-tumor immunity

Peggs, K. S., & Quezada, S. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.109 · Cited by 16

In Vivo Pharmacology Models for Cancer Target Research

Chen, D., An, X., Ouyang, X., Cai, J., Zhou, D., & Li, Q. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9145-7_12 · Cited by 17

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma

Zhang, Y., Wu, X., Sharma, A., Weiher, H., Schmid, M. C., Kristiansen, G., & Schmidt‐Wolf, I. G. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925633 · Cited by 15

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine

Longhitano, E., Muscolino, P., Re, C. L., Ferrara, S. A., Cernaro, V., Gembillo, G., Tessitore, D., Speranza, D., Figura, F., Santarpía, M., et al. (2023) · Cancers · doi:10.3390/cancers15061891 · Cited by 17

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors

Spiga, M., Martini, E., Maffia, M. C., Ciceri, F., Ruggiero, E., Potenza, A., & Bonini, C. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01011-y · Cited by 16

Tumor Macrophages

Qualls, J. E., & Murray, P. J. (2011) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-380916-2.00010-3 · Cited by 15

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

Parmiani, G., Maccalli, C., & Maio, M. (2015) · Vaccines · doi:10.3390/vaccines3020420 · Cited by 15

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma

Chmielowski, B. (2013) · Journal of Skin Cancer · doi:10.1155/2013/423829 · Cited by 15

Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer

Heigener, D., & Reck, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.957187 · Cited by 15

Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature

Matboli, M., El-Nakeep, S. A. K., Hossam, N., Habieb, A., Azazy, A. E., Ebrahim, A. E., Nagy, Z., & Abdel-Rahman, O. M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i26.5896 · Cited by 15

A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment

Yamamoto, S., Matsuo, K., Nagakubo, D., Higashiyama, S., Nishiwaki, K., Oiso, N., Kawada, A., Yoshie, O., & Nakayama, T. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.02.001 · Cited by 15

Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy

Sun, J. X., Kirichenko, D. A., Chung, J. L., Carr, M. J., Eroglu, Z., Khushalani, N. I., Markowitz, J., Messina, J. L., Sondak, V. K., Zager, J. S., et al. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05314-2 · Cited by 16

Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab

Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 16

Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer

Lou, K., Feng, S., Zhang, G., Zou, J., & Zou, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879391 · Cited by 16

Testimony from the Bedside: From Coley's Toxins to Targeted Immunotherapy

Park, J. M., & Fisher, D. E. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.010 · Cited by 15

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke

Bodhankar, S., Chen, Y., Lapato, A. S., Vandenbark, A. A., Murphy, S. J., & Offner, H. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00228 · Cited by 17

Current Strategies to Enhance Anti-Tumour Immunity

Cook, K., Durrant, L. G., & Brentville, V. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020037 · Cited by 15

Immune regulation by dendritic cells and T cells--basic science, diagnostic, and clinical application.

Tuettenberg, A., Becker, C., Correll, A., Steinbrink, K., & Jonuleit, H. (2011) · PubMed · Cited by 15

Immunometabolic Targets in CD8+ T Cells within the Tumor Microenvironment of Hepatocellular Carcinoma

Lin, Y., Ruze, R., Zhang, R., Tuergan, T., Wang, M., Tulahong, A., Zhu, D., Yuan, Z., Jiang, T., Aji, T., et al. (2024) · Liver Cancer · doi:10.1159/000542578 · Cited by 17

CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy

Keilholz, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4fe · Cited by 32

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 448

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 53

Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity

Roddie, C. (2016) · UCL Discovery (University College London)